Vaccine demonstrates potential in delaying relapse of KRAS-mutated pancreatic and colorectal cancers
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center. Results were published today in Nature Medicine.
In the trial, patients with pancreatic and colorectal cancer who were considered at high risk of relapse received a maximum of 10 doses...
